Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 354, Issue 5, pp 543–549 | Cite as

Identification and characterisation of heterogeneous somatostatin binding sites in rat distal colonic mucosa

  • E. S. McKeen
  • W. Feniuk
  • A. D. Michel
  • E. J. Kidd
  • P. P. A. Humphrey
Original Article


We have previously shown that the somatostatin (SRIF) sst2 receptor-selective peptide, BIM-23027, is a potent antisecretory agent in rat isolated distal colonic mucosa (RDCM) and in radioligand binding studies in RDCM membranes, it only maximally inhibited approximately 40% of [125I]-Tyr11-SRIF-14 binding (McKeen ES, Feniuk W, Humphrey PPA (1995) Naunyn-Schmiedeberg's Arch Pharmacol 352:402–411). The aim of this study was to characterise the BIM-23027-sensitive and -insensitive SRIF binding sites in more detail and to compare their properties with those of the recombinant sst2 receptor stably expressed in mouse fibroblast (Ltk) cells.

SRIF-14, SRIF-28, CGP-23996 and D Trp8-SRIF-14 abolished [125I]-Tyr11-SRIF-14 binding (pIC50 values, 8.7–9.7) but the competition curves had Hill slopes which were less than unity. Octreotide and L-362,855 inhibited binding over a wide concentration range (0.1 nM-1 μM) and inhibition of binding was incomplete at the highest concentration studied. BIM-23056 (PIC50 <6.5) was a weak inhibitor of [125]-Tyr11-SRIF-14 binding. GTPγS decreased [125I]-Tyr11-SRIF-14 binding by 40%. Further binding experiments with [125I]-Tyr11-SRIF-14 were carried out in RDCM in the continuous presence of BIM-23027 (1 μM). Under these conditions, seglitide had no effect on [125I]-Tyr11-SRIF-14 binding at concentrations up to 10 μM, whilst SRIF-14 and SRIF-28 abolished specific [125I]-Tyr11-SRIF-14 binding in a manner which was consistent with the ligand binding to two sites. SRIF-14 and SRIF-28 displayed high affinity (pIC50 values of 9.8 and 9.3 respectively) for approximately 70% of these binding sites and low affinity (pIC50 values of 7.8 and 7.3) for the remaining sites. Octreotide, L-362,855 and BIM-23056 were weak inhibitors of [125I]-Tyr11-SRIF-14 binding (PIC50 <6.5). [125I]-BIM-23027 labelled a single population of SRIF binding sites in RDCM membranes and mouse fibroblast (Ltk) cells stably expressing the human recombinant sst2 receptor. There was a significant correlation between the affinitestimates of a range of SRIF analogues at inhibiting [125I]-BIM-23027 binding in RDCM membranes and binding to the recombinant sst2 receptor in Ltk cells, suggesting that the sites labelled by [125I]-BIM-23027 in RDCM are similar to the sst2 receptor. GTPγS (100 μM) decreased [125I]-BIM-23027 binding in RDCM by 60%.

The results from these studies demonstrate that [125I]-Tyr11-SRIF-14 labels a heterogeneous population of high affinity SRIF binding sites in RDCM membranes. The majority of these sites are insensitive to GTPγS and display negligible affinity for the cyclic hexapeptides, BIM-23027 and seglitide. The remaining high affinity binding sites can be selectively labelled with [125I]-BIM-23027, are sensitive to GTPγS and show similar characteristics to the recombinant sst2 receptor which appears to mediate the antisecretory effects of SRIF in the mucosa (McKeen ES, Feniuk W, Humphrey PPA (1995) Naunyn-Schmiedeberg's Arch Pharmacol 352:402–411).

Key words

Somatostatin BIM-23027 Rat colonic mucosa sst2 receptors SRIF-binding 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guilleman R (1973) Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179: 77–79Google Scholar
  2. Brazeau P, Ling N, Esch F, Bohlen P, Benoit R, Guilleman R (1981) High biological activity of synthetic replicates of somatostatin-28 and -25. Regul Pept 1: 255–259Google Scholar
  3. Bruno JF, Xu Y, Song J, Berelowitz M (1992) Molecular cloning and functional expression of a brain-specific somatostatin receptor. Proc Natl Acad Sci USA 89: 11151–11155Google Scholar
  4. Bruno JF, Xu Y, Song J, Berelowitz M (1993) Tissue distribution of somatostatin receptor subtype messenger ribonucleic acid in the rat. Endocrinology 133: 2561–2567Google Scholar
  5. Castro SW, Buell G, Feniuk W, Humphrey PPA (1995) Differences in the operational characteristics of the human recombinant somatostatin receptor types, sst1 and sst2, in mouse fibroblast (Ltk) cells. Br J Pharmacol 117: 639–646Google Scholar
  6. Eliakim R, Karmeli F, Okon E, Rachmilewitz D (1993) Octreotide effectively decreases mucosal damage in experimental colitis. Gut 34: 264–269Google Scholar
  7. Gyr KE, Meier R (1993) Pharmacodynamic effects of Sandostatin in the gastrointestinal tract. Digestion 54: 14–19Google Scholar
  8. Hoyer D, Lübbert H, Bruns C (1994) Molecular pharmacology of somatostatin receptors. Naunyn-Schmiedeberg's Arch Pharmacol 350: 441–453Google Scholar
  9. Hoyer D, Bell GI, Berelowitz M, Epelbaum J, Feniuk W, Humphrey PPA, O'Carroll A-M, Patel YC, Schonbrunn A, Taylor JE, Reisine T (1995) Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 16: 86–88Google Scholar
  10. McKeen ES, Feniuk W, Humphrey PPA (1995) Somatostatin receptors mediating inhibition of basal and stimulated electrogenic ion transport in rat distal colonic mucosa. Naunyn-Schmiedeberg's Arch Pharmacol 352: 402–411Google Scholar
  11. Michel AD, Whiting RL (1984) Analysis of ligand binding data using a microcomputer. Br J Pharmacol 108: 144PGoogle Scholar
  12. Munson PJ, Rodbard D (1980) A versatile computerised approach for characterisation of ligand-binding systems. Anal Biochem 107: 220–239Google Scholar
  13. Palmer SJ, Solomon TE (1988) Effects of gastrin, proglumide and somatostatin on growth of human colonic cancer. Gastroenterology 95: 1541–1548Google Scholar
  14. Patel YC, Greenwood M, Kent G, Panetta R, Srikant CB (1993) Multiple gene transcripts of the somatostatin receptor SSTR2: Tissue selective distribution and cAMP regulation. Biophys Res Common 192: 288–294Google Scholar
  15. Raulf F, Pérez J, Hoyer D, Bruns C (1994) Differential expression of five somatostatin receptor subtypes, SSTRI-5, in the CNS and peripheral tissue. Digestion 55: 46–53Google Scholar
  16. Raynor K, Reisine T (1989) Analogs of somatostatin selectively label distinct subtypes of somatostatin receptors in rat brain. J Pharm Exp Ther 251: 510–517Google Scholar
  17. Raynor K, Coy DC, Reisine T (1992) Analogues of somatostatin bind selectively to brain somatostatin receptor subtypes. J Neurochem 59: 1241–1250Google Scholar
  18. Raynor K, Murphy WA, Coy DH, Taylor JE, Moreau J-P, Yasuda K, Bell GI, Reisine T (1993a) Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides. Mol Pharmacol 43: 838–844Google Scholar
  19. Raynor K, O'Carroll A-M, Kong H, Yasuda K, Mahan LC, Bell GI, Reisine T (1993b) Characterization of cloned somatostatin receptors SSTR4 and SSTR5. Mol Pharmacol 44: 385–392Google Scholar
  20. Rens-Domiano S, Law SF, Yamada Y, Seino S, Bell GI, Reisine T (1992) Pharmacological properties of two cloned SRIF receptors. Mol Pharmacol 42: 28–34Google Scholar
  21. Reubi JC (1984) Evidence for two somatostatin-14 receptor types in rat brain cortex. Neurosci Lett 49: 259–263Google Scholar
  22. Reubi JC (1985) New specific radioligand for one subpopulation of brain somatostatin receptors. Life Sci 36: 1829–1834Google Scholar
  23. Reubi JC, Horisberger U, Waser B, Gebbers JO, Laissue J (1992) High affinity somatostatin receptors in human gut-associated lymphoid tissues; preferential location in germinal centres. Gastroenterology 103: 1207–1214PubMedGoogle Scholar
  24. Reubi JC, Mazzucchelli L, Laissue J (1994a) Intestinal vessels express a high density of somatostatin receptors in human inflammatory bowel disease. Gastroenterology 106: 951–959Google Scholar
  25. Reubi JC, Schaer B, Waser JC, Mengod G (1994b) Expression and localisation of somatostatin receptor SSTR1, SSTR2 and SSTR3 messenger RNAs in primary human tumours using in situ hybridisation. Cancer Res 54: 3455–3459Google Scholar
  26. Strader CD, Dixon RA, Cheung AH, Candlelone MR, Blake AD, Sigal ID (1987) Mutations that uncouples the β-adrenergic receptor from Gs and increase agonist affinity. J Biol Chem 262: 16439–16443Google Scholar
  27. Tran VT, Beal MF, Martin JB (1985) Two types of somatostatin receptors differentiated by cyclic somatostatin analogs. Science 228: 492–495Google Scholar
  28. Warhurst G, Turnberg LA, Higgs NB, Tonge A, Grundy J, Fog KE (1993) Multiple G-protein-dependent pathways mediate the antisecretory effect of somatostatin and clonidine in the HT29–19A colonic cell line. J Clin Invest 92: 603–611Google Scholar
  29. Warhurst G, Higgs NB, Grigor MR, Ross T, Barbezat GD (1995) Expression of multiple somatostatin receptor genes in human colonic epithelial cells. Biochem Soc Trans 23: 18SGoogle Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • E. S. McKeen
    • 1
  • W. Feniuk
    • 1
  • A. D. Michel
    • 1
  • E. J. Kidd
    • 1
  • P. P. A. Humphrey
    • 1
  1. 1.Glaxo Institute of Applied Pharmacology, Department of PharmacologyUniversity of CambridgeCambridgeUK

Personalised recommendations